Tariq Javed, MD
Nephrology · Visalia, CANPI 1891973806
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Otsuka America Pharmaceutical, Inc. accounts for 87.0% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $7,817 and has fallen 99.6% since, to $29 in 2025.
Across 68 payments — averaging $145.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$9K
- AstraZeneca$459
- Johnson & Johnson$186
- Intercept Pharmaceuticals, Inc.$125
- Fresenius USA Marketing, Inc.$98
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$96
- plus $322 from 11 others
Across 9 payments — averaging $1453.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$13K
What the payments were for
- Speaking & faculty fees$5,93860%
- Travel & lodging$2,26123%
- Food & beverage$1,54716%
- Education$1802%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 23 | $8,640 |
| AstraZeneca(2 entities) | 16 | $459 |
| Johnson & Johnson | 10 | $186 |
| Intercept Pharmaceuticals, Inc. | 1 | $125 |
| Fresenius USA Marketing, Inc. | 1 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $96 |
| OPKO Pharmaceuticals, LLC | 2 | $76 |
| Pfizer | 3 | $45 |
| Amgen | 3 | $43 |
| Abiomed | 1 | $29 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Novartis | 1 | $19 |
| Baxter Healthcare | 1 | $18 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,926 in reported general payments places this provider in the 85th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 118 | $272,921 |
| FarxigaDapagliflozin Propanediol | 125 | $137,341 |
| Sevelamer Hcl | 46 | $107,361 |
| LokelmaSodium Zirconium Cyclosilicate | 103 | $95,750 |
| XphozahTenapanor Hcl | 24 | $70,173 |
| ProcritEpoetin Alfa | 84 | $59,693 |
| Sevelamer Carbonate | 220 | $52,974 |
| ProsolParenteral Amino Acid 20% No.1 | 197 | $33,602 |
| JardianceEmpagliflozin | 31 | $29,286 |
| VeltassaPatiromer Calcium Sorbitex | 20 | $24,731 |
| RetacritEpoetin Alfa-Epbx | 46 | $22,256 |
| Calcium Acetate | 213 | $18,120 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 57 | $14,580 |
| Lanthanum Carbonate | 17 | $13,319 |
| JanuviaSitagliptin Phosphate | 11 | $10,943 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $98 | $272,921118 claims |
| AstraZenecaFarxiga, Lokelma | $459 | $233,091228 claims |
| Johnson & JohnsonProcrit | $186 | $59,69384 claims |
| PfizerRetacrit | $45 | $22,25646 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,341 nephrology providers in California.
Other nephrology in Visalia
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.